Brain health company Angelini Pharma has announced a strategic collaboration with biotechnology company Quiver Bioscience to discover and advance novel therapeutics to genetic epilepsies. The collaboration, which also includes a licensing agreement, brings together Quiver’s drug discovery capabilities, data assets and AI models with Angelini Pharma’s expertise in brain health and… Read More
Biotechnology company Soley Therapeutics has raised $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into clinic. It is believed Soley intends to use the funds to support its work filing investigational new drug (IND) applications and its… Read More
Biopharmaceuticals company DISCO Pharmaceuticals has entered an exclusive license agreement with biotech company Amgen to advance novel cancer targeted therapies. The companies aim to develop the therapies for a target mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms… Read More
Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division at BioDuro, explore the advantages of a unified FBDD workflow. Read More
On 30 June 2025, The Milner Therapeutics Institute hosted its annual symposium, a hybrid event hosted at West Road Concert Hall in Cambridge, UK, to bring together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics. The day featured a line-up of speakers,… Read More
Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers… Read More
DDW was delighted to work with CN Bio on an exclusive event which focused on novel approaches to human lung disease modelling. The free event took place on 29 March at 3pm. It covered: Accelerating the discovery of new therapeutics for treatment… Read More
The startup company Novel Concepts Medical has announced breakthroughs in its research of Covid-19, which include stopping Covid-19, the Omicron Variant, and long Covid-19 symptoms, including memory loss. The treatment Its novel plant-based treatment has resulted in successfully inhibiting the Covid-19 Omicron variant and blocking… Read More
Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox. Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of… Read More
Scientists from Queen’s University Belfast have developed a computer-aided data tool that will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects. The data tool or protocol will uncover a novel class of… Read More
Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Liu is Professor of Precision Biomedicine with… Read More
Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL). Drug candidates with… Read More
An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected… Read More
News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More
Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More
PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021… Read More
